Antibiotic combo by Forest, AstraZeneca is set for Phase III testing

10/18/2011 | Reuters

Forest Laboratories and partner AstraZeneca are ready to start Phase III clinical testing of CAZ-AVI, a superbug-fighting antibiotic that combines avibactam and ceftazidime. The drug will be tested on hospitalized patients with urinary tract or abdominal infection caused by gram-negative bacteria. The drugmakers aim for a regulatory submission in 2014.

View Full Article in:


Published in Brief: